secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-05-22T20:00:36+00:00
Accession:  0001437749-26-018242
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech ASCO abstract on Annamycin cardiac safety shows no cardiotoxicity in 90 patients
--------------------------------------------------------------------------------

- Abstract accepted for poster at 2026 ASCO Annual Meeting (May 29–June 2, Chicago).
- Pooled safety analysis of 90 Annamycin patients; median cumulative dose 660 mg/m2.
- No significant LVEF change from baseline (mean diff -0.12%, p=0.84); no dose correlation.
- CEO highlights potential to provide anthracycline therapy without cardiotoxicity limits.
- Company's Phase 1b/2 AML study previously showed 50% CR and median OS of 12.39 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/0001437749-26-018242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926018242/mbrx20260522_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer